Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses 2022, 14, 177

Niklas Jäger; Markus Hoffmann; Stefan Pöhlmann; Nadine Krüger

doi:10.3390/v14071526

Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses 2022, 14, 177

Viruses. 2022 Jul 13;14(7):1526. doi: 10.3390/v14071526.

Authors

Niklas Jäger^{1

2}, Markus Hoffmann^{1

2}, Stefan Pöhlmann^{1

2}, Nadine Krüger¹

Affiliations

¹ Infection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
² Faculty of Biology and Psychology, Georg-August-University, 37073 Göttingen, Germany.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, which has been reported to have caused 18 [...].

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Benzamidines
COVID-19*
Chlorocebus aethiops
Frameshifting, Ribosomal
Guanidines
Humans
SARS-CoV-2* / genetics
Vero Cells
Virus Replication

Substances

Benzamidines
Guanidines
nafamostat

Grants and funding

This research was funded by the DFG Priority program “Innate Sensing and Restriction of Retroviruses” (SPP 1923, project no. 429513786), the Federal Ministry of Education and Research (BMBF; Grant Number 01KI2006D and 01KI20328A) and the Ministry of Lower Saxony (MWK; Grant Number 6FF22).